Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
179.71
+1.98 (1.11%)
At close: Sep 26, 2025, 4:00 PM EDT
179.94
+0.23 (0.13%)
After-hours: Sep 26, 2025, 7:58 PM EDT
Johnson & Johnson Employees
Johnson & Johnson had 138,100 employees as of December 31, 2024. The number of employees increased by 6,200 or 4.70% compared to the previous year.
Employees
138,100
Change (1Y)
6,200
Growth (1Y)
4.70%
Revenue / Employee
$656,242
Profits / Employee
$164,091
Market Cap
432.80B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 138,100 | 6,200 | 4.70% |
Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
Dec 31, 2022 | 152,700 | 11,000 | 7.76% |
Dec 31, 2021 | 141,700 | 7,200 | 5.35% |
Dec 31, 2020 | 134,500 | 2,300 | 1.74% |
Dec 29, 2019 | 132,200 | -2,900 | -2.15% |
Dec 30, 2018 | 135,100 | 1,100 | 0.82% |
Dec 31, 2017 | 134,000 | 7,600 | 6.01% |
Dec 31, 2016 | 126,400 | -700 | -0.55% |
Dec 31, 2015 | 127,100 | 600 | 0.47% |
Dec 28, 2014 | 126,500 | -1,600 | -1.25% |
Dec 29, 2013 | 128,100 | 500 | 0.39% |
Dec 30, 2012 | 127,600 | 9,700 | 8.23% |
Dec 31, 2011 | 117,900 | 3,900 | 3.42% |
Dec 31, 2010 | 114,000 | -1,500 | -1.30% |
Dec 31, 2009 | 115,500 | -3,200 | -2.70% |
Dec 28, 2008 | 118,700 | -500 | -0.42% |
Dec 30, 2007 | 119,200 | -3,000 | -2.45% |
Dec 31, 2006 | 122,200 | 6,600 | 5.71% |
Dec 31, 2005 | 115,600 | 5,600 | 5.09% |
Dec 31, 2004 | 110,000 | -1,000 | -0.90% |
Dec 28, 2003 | 111,000 | 3,000 | 2.78% |
Dec 29, 2002 | 108,000 | 6,000 | 5.88% |
Dec 30, 2001 | 102,000 | 1,000 | 0.99% |
Dec 31, 2000 | 101,000 | 3,200 | 3.27% |
Dec 31, 1999 | 97,800 | 4,700 | 5.05% |
Dec 31, 1998 | 93,100 | 2,600 | 2.87% |
Dec 28, 1997 | 90,500 | 1,200 | 1.34% |
Dec 29, 1996 | 89,300 | 7,000 | 8.51% |
Dec 31, 1995 | 82,300 | 800 | 0.98% |
Dec 31, 1994 | 81,500 | -100 | -0.12% |
Dec 31, 1993 | 81,600 | -3,300 | -3.89% |
Dec 31, 1992 | 84,900 | 2,200 | 2.66% |
Dec 31, 1991 | 82,700 | 500 | 0.61% |
Dec 31, 1990 | 82,200 | -900 | -1.08% |
Dec 31, 1989 | 83,100 | 1,800 | 2.21% |
Dec 31, 1988 | 81,300 | 3,100 | 3.96% |
Dec 31, 1987 | 78,200 | 1,100 | 1.43% |
Dec 31, 1986 | 77,100 | 2,200 | 2.94% |
Dec 31, 1985 | 74,900 | 700 | 0.94% |
Dec 31, 1984 | 74,200 | -3,200 | -4.13% |
Dec 31, 1983 | 77,400 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
JNJ News
- 3 days ago - Johnson & Johnson (JNJ) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - J&J to withdraw acid reflux device from non-US markets, Bloomberg News reports - Reuters
- 5 days ago - These are the top 22 stocks pushing the S&P 500 into record territory — and it's not all Big Tech - Market Watch
- 8 days ago - TREMFYA® (guselkumab) achieves U.S. approval for subcutaneous induction in adults with ulcerative colitis, now the first and only IL-23 inhibitor with a fully subcutaneous regimen - PRNewsWire
- 8 days ago - TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma - PRNewsWire
- 8 days ago - Johnson & Johnson receives positive CHMP opinion of nipocalimab to treat a broad population of antibody-positive patients living with generalised myasthenia gravis (gMG) - GlobeNewsWire
- 10 days ago - J&J's experimental psoriasis drug shows promise against Bristol's treatment - Reuters
- 10 days ago - Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis - PRNewsWire